Erratum: Early onset HER2-positive breast cancer is associated with germline TP53 mutations (Cancer DOI: 10.1002/cncr.26377);Early onset HER2-positive breast cancer is associated with germline TP53 mutations

Cancer

Volumn 118, Issue 4, 2012, Pages 908-913

  Melhem Bertrandt, Amal ^a   Bojadzieva, Jasmina ^a   Ready, Kaylene J ^a   Obeid, Elias ^b   Liu, Diane D ^a   Gutierrez Barrera, Angelica M ^a   Litton, Jennifer K ^a   Olopade, Olufunmilayo I ^a   Hortobagyi, Gabriel N ^a   Strong, Louise C ^a   Arun, Banu K ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

BRCA1 2 mutation; germline TP53 mutation; HER2 positive breast cancer; Li Fraumeni syndrome

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER GENETICS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE AMPLIFICATION; GENE LOCATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ONCOGENE; ONCOGENE NEU; ONSET AGE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TP53 GENE; COHORT ANALYSIS; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; GENE EXPRESSION; GERMLINE MUTATION; MAJOR CLINICAL STUDY; TUMOR SUPPRESSOR GENE;

EID: 84856770553     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26534     Document Type: Erratum

References (27)

1. Li FP, Fraumeni JF Jr,. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst. 1969; 43: 1365-1373.
2. Birch JM, Blair V, Kelsey AM, et al. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene. 1998; 17: 1061-1068.
3. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M,. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007; 26: 2157-2165.
4. Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP,. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst. 1998; 90: 606-611.
5. Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003; 63: 6643-6650.
6. Ruijs MW, Verhoef S, Rookus MA, et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet. 2010; 47: 421-428.
7. Fackenthal JD, Olopade OI,. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer. 2007; 7: 937-948.
8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: genetic/familial high risk assessment: breast and ovarian. Version 1.2010. Available at:. Accessed January 2011.
9. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009; 27: 1250-1256.
10. Eeles RA,. Germline mutations in the TP53 gene. Cancer Surv. 1995; 25: 101-124.
11. rd Annual San Antonio Breast Cancer Symposium; December 10, 2010; San Antonio, TX.
12. Wilson JR, Bateman AC, Hanson H, et al. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet. 2010; 47: 771-774.
13. Hwang SJ, Lozano G, Amos CI, Strong LC,. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet. 2003; 72: 975-983.
14. Olivier M, Petitjean A, Marcel V, et al. Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther. 2009; 16: 1-12.
15. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98: 10869-10874.
16. Nakopoulou LL, Alexiadou A, Theodoropoulos GE, Lazaris AC, Tzonou A, Keramopoulos A,. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer. J Pathol. 1996; 179: 31-38.
17. Geisler S, Lonning PE, Aas T, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 2001; 61: 2505-2512.
18. Langerod A, Zhao H, Borgan O, et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res. 2007; 9: R30.
19. Fernandez-Cuesta L, Anaganti S, Hainaut P, Olivier M,. p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines. Int J Cancer. 2011; 128: 1813-1821.
20. Chang F, Syrjanen S, Kurvinen K, Syrjanen K,. The p53 tumor suppressor gene as a common cellular target in human carcinogenesis. Am J Gastroenterol. 1993; 88: 174-186.
21. International Agency for Research on Cancer. IARC TP53 database. Available at:. Accessed February 2011.
22. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007; 28: 622-629.
23. Goldstein I, Marcel V, Olivier M, Oren M, Rotter V, Hainaut P,. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther. 2011; 18: 2-11.
24. Margolies L, Ha R,. Breast magnetic resonance imaging: an overview for nonradiologists. Mt Sinai J Med. 2009; 76: 598-605.
25. Heymann S, Delaloge S, Rahal A, et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol. 2010; 5: 104.
26. Shahabi V, Seavey MM, Maciag PC, Rivera S, Wallecha A,. Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human. Cancer Gene Ther. 2011; 18: 53-62.
27. Masciari S, Van den Abbeele AD, Diller LR, et al. F18-fluorodeoxyglucose- positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA. 2008; 299: 1315-1319.